Breast Cancer: Weight and Exercise. Anne McTiernan, MD, PhD. Fred Hutchinson Cancer Research Center Seattle, WA
|
|
- Stewart Powell
- 5 years ago
- Views:
Transcription
1 Breast Cancer: Weight and Exercise Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA
2 Associations of Obesity with Overall & Breast Cancer Specific Survival
3 Survival Obese vs. Non-obese Breast Cancer Patients by Hormone Receptor Niraula et al. BCRT 2012;134:769-81
4 Survival Obese vs. Non-obese Breast Cancer Patients by Menopausal Status Niraula et al. BCRT 2012;134:769-81
5 Breast Cancer Specific Survival Obese vs. Non-obese Breast Cancer Patients by Hormone Receptor Niraula et al. BCRT 2012;134:769-81
6 Breast Cancer Specific Survival Obese vs. Non-obese Breast Cancer Patients by Menopausal Status Niraula et al. BCRT 2012;134:769-81
7 HEAL Cohort 1183 newly diagnosed breast cancer patients 3 centers: FHCRC, New Mexico, Los Angeles Population-based (registries) Multi-ethnic Followed for ~ 10 years post-diagnosis Assessing effect on prognosis of: weight, physical activity, metabolic hormones, inflammation, sex hormones, nutrition, vitamin D
8 BMI and Risk of Death, HEAL Cohort of Breast Cancer Patients, N=645, Followed Mean 8.5 Years Smith et al, submitted.
9 BMI & Recurrence: Non-inflammatory Locally Advanced and Inflammatory: MD Anderson (N=602) Dawood S et al. Clin Cancer Res 2008;14: by American Association for Cancer Research
10 Obesity & Treatments
11 Obesity in N 0, ER+ Breast Cancer: Tamoxifen Efficacy
12 Survival by BMI: Neoadjuvant Breast Cancer Patients MD Anderson Series Litton, J. K. et al. J Clin Oncol; 26: Copyright American Society of Clinical Oncology
13 BMI in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: BIG trial, N=2,887 A: overall survival B: disease-free survival de Azambuja et al. Br Ca Res Treat 2009
14 Overweight/obese by Treatment (tamoxifen, anastrozole) & Survival: ABCSG-12 Trial (n=1803) Pfeiler G et al. JCO 2011;29: by American Society of Clinical Oncology
15 Hazard Plots for Anastrozole vs Tamoxifen by BMI: All & Distant Recurrences Sestak I et al. JCO 2010;28: by American Society of Clinical Oncology
16 Weight Change after Diagnosis and Breast Cancer Prognosis 4/8 studies: significant decreased survival/ increased recurrence with weight gain Nurses Health Study, n=5204, followed ~ 9 years, risk or death for BMI gain in non-smokers: kg/m 2 : 1.35 > 2.0 kg/m 2 : 1.64 LACE cohort, stage 1-3, n=1689, followed ~ 7 years Weight loss > 10%: 2.5 x increased risk of death in ER- /PR- patients Chlebowski, Aiello, McTiernan JCO 2002;20(4): Kroenke et al. J. Clin Onc 2005;23(7): Caan B et al. Ca Causes Cont 2008:19:
17 Other Potential Adverse Effects of Obesity in Breast Cancer Wound complications Lymphedema Radiation therapy challenges? Endometrial cancer in tamoxifen users Congestive heart failure in patients treated with doxorubicin Increased risk for coronary disease, diabetes, stroke, hypertension, osteoarthritis, several cancers, decreased quality of life
18 Weight & Prognosis: Summary Overweight/obese/underweight prognosis Weight gain after diagnosis Purposeful weight loss after diagnosis???
19 Weight & Prognosis: Summary Weight effects seen in: Pre-menopausal Postmenopausal All stages Hormone receptor positive & negative Varied treatments including surgery, chemotherapy, hormonal agents Population & clinical trial cohorts Cheblowski, Aiello, McTiernan JCO 2002;20(4): Niraula et al. BCRT 2012;134:769-81
20 Potential Mechanisms of Obesity- Prognosis Link Estrogens, androgens Hyper-insulinemia, insulin resistance, diabetes, pre-diabetes Inflammatory markers Diet/physical activity
21 Hazard Ratio Risk of Breast Cancer Death by C-peptide (HEAL, 571 stage I-IIIa patients, followed up mean 4.1 years) C-peptide P trend = 0.03 Irwin et al. J Clin Oncol 2011; 29(1):47-53 < 1.7 ng/ml ng/ml > 2.5 ng/ml Diabetics
22 Risk of Death by C-Reactive Protein (HEAL, 734 stage I-IIIa patients, followed up mean 3.8 years) 2.5 P trend =0.01 Hazard Ratio < 1.2 mg/l mg/l > 3.9 mg/l 0 Met-hr/wk Pierce et al. J Clin Oncol 2009; 27(21):
23 HEAL Study Weight Change (kg) in 2 Years after Diagnosis, by Stage P=0.004 Stage in situ Stage I Stage II-IIIa Irwin, M. L. et al. J Clin Oncol; 23:
24 Fasting Glucose and Breast Cancer Outcomes Population: 512 early stage breast cancer no known diabetes Results: Quartile DDFS OS Mean Range HR (adjusted)* (95% CI) HR (adjusted)* (95% CI) ( ) 1.26 ( ) ( ) 1.46 ( ) ( ) 1.81 ( ) p=0.027 unadjusted p=0.034 adjusted p=0.036 unadjusted p=0.014 adjusted * adjusted for age, T, N, grade, hormone receptor, chemotherapy, hormone therapy Goodwin PJ et al. J Clin Oncol 2012
25 Low-Fat Diet and Breast Cancer Prognosis: the WINS Study Clinical trial 2,437 women with early stage breast cancer Recruited from 37 U.S. sites years old Randomly assigned to low-fat diet or control group 6 lb. greater weight loss at 12 mos. in intervention vs. control women Followed for up to 5 years Risk of death was significantly reduced by 24 percent in diet patients vs. controls
26 High Vegetable/Lower Fat Diet: the WHEL Study Multi-site clinical trial 3088 women with early stage breast cancer years old Randomly assigned to high vegetable/fruit/fiber, low-fat diet or control group Followed for a mean 7.3 years Little change in diet vs. control diets No effect of diet on prognosis Pierce et al. JAMA Jul 18;298(3):
27 Alcohol & Breast Cancer Prognosis Recent findings suggest alcohol use (> 1 drink/d) associated with: Increased recurrence Increased contralateral/2 nd primary breast cancer Moderate alcohol use may be associated with reduced mortality Li et al. JCO 2009;27: Kwan et al. JCO 2010;28(29): Barnett et al. JCO 2008; 26:
28 Physical Activity & Breast Cancer Survival Ballard-Barbash R, et al. JNCI Jun 6;104(11):815-40
29 Other Exercise Effects in Survivors week aerobic exercise program results in: Improved fitness Moderate weight and fat loss Increased lean mass Reduced fatigue Improved mood Improved overall quality of life Galvao et al. JCO 2005;23: (review)
30 Total Physical Activity Before and After Diagnosis in Breast Cancer Survivors by Treatment (HEAL) Hours/week P<.05 Surgery Surgery + Radiation Treatment P<.05 Surgery + Chemo Irwin M. et al. Cancer 2003;97: Before Diagnosis After Diagnosis
31 Treatments Available for Conditions (None FDA Approved for Breast Cancer) Reduce/treat obesity: Reduced calorie diet Physical activity Weight loss therapies (extreme obesity or co-morbidities Xenical/Alli (orlistat, blocks fat absorption prescription & OTC) Qsymia (topiramate, an anti-convulsant & phentermine, an appetite suppressant) Belviq (lorcaserin hydrochloride, activates serotonin 2C receptor) Bariatric surgery Note: all for adding to diet & exercise weight loss program Medications to treat obesity mediators: Excess insulin (Metformin - NCIC trial ongoing) Inflammation (Statins, NSAIDS)
32 Implementing Lifestyle Change Reduced calorie (~ kcal/day) Increased physical activity (>150 minutes/week moderate intensity) Strength training does not increase lymphedema (progress slowly) Weekly meetings with counselor Self-monitoring: Daily diet logs all foods and drinks Weighing at least weekly Daily exercise logs - recreational/walking activity Goal 7%-10% weight loss in 6 months Studies in breast cancer survivors show lower weight loss than in persons without cancer
33 Conclusions: Clinical Guidelines During chemo/radiation: Avoid weight gain unless underweight Exercise as tolerated: start slowly, increase slowly After or no chemo/radiation: Lose weight if BMI > 25.0 through calorie reduction + increased physical activity Aerobic exercise at least 30 min/day, 5 days/wk Gradually increase to moderate intensity (e.g. brisk walking, biking, fast dancing) Long-term survivors: weight loss may lower estrogens, beneficial for patients who have completed hormone therapy Keep alcohol to 1 drink/day or less
Breast Cancer: Weight and Exercise. Anne McTiernan, MD, PhD. Fred Hutchinson Cancer Research Center Seattle, WA
Breast Cancer: Weight and Exercise Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA Associations of Obesity with Overall & Breast Cancer Specific Survival Survival Obese vs. Non-obese
More informationLifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival
Lifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival Melinda L. Irwin, PhD, MPH Associate Professor of Epidemiology Yale School of Medicine
More informationPhysical Activity & Cancer What We Know, What We Don t Know. Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA
Physical Activity & Cancer What We Know, What We Don t Know Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA What We Know Extensive epidemiologic research on relationship between
More informationLifestyle Risk Factors and Cancer Prevention
February 3-5, 2016 Lansdowne Resort, Leesburg, VA Lifestyle Risk Factors and Cancer Prevention Melinda L. Irwin, PhD, MPH Professor of Epidemiology, Yale School of Public Health, Associate Director (Population
More informationObesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities Sao Jiralerspong and Pamela J. Goodwin
VOLUME 34 NUMBER 35 DECEMBER 10, 2016 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities Sao Jiralerspong and Pamela J.
More informationBreast Cancer Survivorship
Breast Cancer Survivorship Melissa Accordino, MD Assistant Professor of Medicine Herbert Irving Comprehensive Cancer Center Columbia University Medical Center Who are the Cancer Survivors? More than 1
More informationTerapia Hormonal da Paciente Premenopausa
I Congresso de Oncologia D Or 5 e 6 de julho de 2013 Terapia Hormonal da Paciente Premenopausa Antonio C. Wolff, MD, FACP, FASCO Professor de Oncologia Programa de Câncer de Mama Johns Hopkins University
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationLow-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers
Low-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers Ross Prentice Fred Hutchinson Cancer Research Center and University of Washington AICR, November 5, 2009 Outline
More informationEvidence for the Role of Obesity in Breast Cancer Progression
Evidence for the Role of Obesity in Breast Cancer Progression Pamela J. Goodwin, M.D., M.Sc., F.R.C.P.C. Professor of Medicine Mount Sinai and Princess Margaret Hospitals University of Toronto BMI and
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationPhysical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA
Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000
More informationNew Insights into Breast Cancer Risk Reduction
New Insights into Breast Cancer Risk Reduction November 10, 2013 Rowan T. Chlebowski Professor of Medicine David Geffen School of Medicine at UCLA Chief, Division of Medical Oncology and Hematology Harbor-UCLA
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationAnthropometry: What Can We Measure & What Does It Mean?
Anthropometry: What Can We Measure & What Does It Mean? Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, Washington, U.S.A. I have no conflicts to disclose. Anthropometry in Human
More informationLeveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology
Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology Charles S. Fuchs, MD, MPH Director, Yale Cancer Center Physician-in-Chief, Smilow Cancer Hospital New
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationPamela J. Goodwin, M.D., M.Sc., F.R.C.P.C.
Overview of the Evidence Relating Cancer Outcomes to Obesity and Body Weight Pamela J. Goodwin, M.D., M.Sc., F.R.C.P.C. Professor of Medicine University of Toronto Obesity Trends* Among U.S. Adults BRFSS,
More informationBreast Cancer Survivorship: Physical Activity
WORKING EVERYDAY TO PROVIDE THE HIGHEST QUALITY OF LIFE FOR PEOPLE WITH CANCER Breast Cancer Survivorship: What is the Role of Diet and Physical Activity WENDY DEMARK-WAHNEFRIED, PHD, RD PROFESSOR AND
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationExercise as Medicine for Cancer Management. Robert U. Newton, PhD
Exercise as Medicine for Cancer Management Robert U. Newton, PhD What is Anabolic Exercise? Repetitive movements performed against resistance Resistance limits number completed e.g. 10 reps per set (10RM)
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationEating and Exercising toward Better Health in Cancer Survivors
W O R K I N G E V E R Y D A Y T O P R O V I D E T H E H I G H E S T Q U A L I T Y O F L I F E F O R P E O P L E W I T H C A N C E R Eating and Exercising toward Better Health in Cancer Survivors W E N
More informationSoyfood Consumption and Breast Cancer Survival. Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A.
Soyfood Consumption and Breast Cancer Survival Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A. Objectives Brief summary of the health benefits of soyfood consumption
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationOptimal Nutritional Goals for the Cancer Survivor
W O R K I N G E V E R Y D A Y T O P R O V I D E T H E H I G H E S T Q U A L I T Y O F L I F E F O R P E O P L E W I T H C A N C E R Optimal Nutritional Goals for the Cancer Survivor W E N D Y D E M AR
More informationHealth status and Healthcare utilization of Breast cancer survivors
Health status and Healthcare utilization of Breast cancer survivors 2017.4.22 Jihyoun Lee Breast Center, department of surgery Soonchunhyang University Seoul Hospital Issues in cancer survivors Persistent
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationLife after treatment for Ovarian Cancer: Cancer Survivorship. Anne Blaes MD, MS
Life after treatment for Ovarian Cancer: Cancer Survivorship Anne Blaes MD, MS Goals 1. To gain an understanding of potential late effects of cancer therapy 2. To gain an understanding of a cancer survivorship
More informationHow do we adapt diet approaches for patients with obesity with or without diabetes? Therese Coleman Dietitian
How do we adapt diet approaches for patients with obesity with or without diabetes? Therese Coleman Dietitian Developing a specialist weight management programme How did we adapt dietary approaches for
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationPhysical Activity, Biomarkers, and Disease Outcomes in Cancer Survivors: A Systematic Review
JNCI Journal of the National Cancer Institute Advance Access published May 8, 2012 DOI: 10.1093/jnci/djs207 Published by Oxford University Press 2012. REVIEW Physical Activity, Biomarkers, and Disease
More informationWEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationIncreased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017
Increased Risk of Breast Cancer: Screening and Prevention Elizabeth Pritchard, MD 4/5/2017 No disclosures Defining Risk Risk Factors Modifiable Lifestyle obesity physical activity alcohol consumption breast
More informationSoyfood Consumption and Breast Cancer Survival. Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A.
Soyfood Consumption and Breast Cancer Survival Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A. Objectives Brief summary of the health benefits of soyfood consumption
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 29 OCTOBER 10 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Alcohol Consumption and Breast Cancer Recurrence and Survival Among Women With Early-Stage Breast Cancer: The
More informationIssues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010
Issues in Cancer Survivorship Larissa A. Korde, MD, MPH June 26, 2010 Estimated US Cancer Cases in Women: 2006-2008 CA Cancer J Clin 2006; 56:106-130; CA Cancer J Clin 2008;58:71 96. Relative Survival*
More informationATAC Trial. 10 year median follow-up data. Approval Code: AZT-ARIM-10005
ATAC Trial 10 year median follow-up data Approval Code: AZT-ARIM-10005 Background FDA post-approval commitment analysis to update DFS, TTR, OS and Safety Prof. Jack Cuzick on behalf of ATAC/LATTE Trialists
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationChapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence
Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence 2.1 BMI and Breast Cancer Risk BMI is routinely used to qualify an individual s adiposity, yet it is simply a measure
More informationJournal of Clinical Oncology
Journal of Clinical Oncology Copy of e-mail Notification zlj7630 Your article (# 59822) from Journal of Clinical Oncology is available for download ===== Journal of Clinical Oncology Article no. 59822
More informationNIH Public Access Author Manuscript Breast Cancer Res Treat. Author manuscript; available in PMC 2012 February 5.
NIH Public Access Author Manuscript Published in final edited form as: Breast Cancer Res Treat. 2011 November ; 130(1): 195 205. doi:10.1007/s10549-011-1557-4. Multivitamin Use and Breast Cancer Outcomes
More informationSurvivorship and Breast Cancer in Older Patients
Survivorship and Breast Cancer in Older Patients Michelle Melisko MD Clinical Professor of Medicine UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Research support: Nektar, Novartis,
More informationDOES NEOADJUVANT Rx REALLY DOWN STAGE BR CA? DR KHANYILE DEPARTMENT OF MEDICAL ONCOLOGY, University of Pretoria
DOES NEOADJUVANT Rx REALLY DOWN STAGE BR CA? DR KHANYILE DEPARTMENT OF MEDICAL ONCOLOGY, University of Pretoria BREAST CA STAGING TNM STAGING: - T x N - x - 0-0 - is - 1-1(1mic/1a/1b/1c) - 2(a/b) - 2-3(a/b/c)
More informationHORMONAL THERAPY IN ADJUVANT CARE
ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER* Matthew J. Ellis, MD, PhD ABSTRACT Endocrine therapy is used frequently in breast cancer management, particularly in the setting of adjuvant care, but outstanding
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationDisclosures. Start the Conversation. Agenda. Behavioral and Medical Approaches for Obesity Treatment 10/18/2014
Disclosures Behavioral and Medical Approaches for Obesity Treatment Scott Kahan, MD, MPH Director, National Center for Weight and Wellness Clinical Director, Strategies To Overcome and Prevent (STOP) Obesity
More informationWhat Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
More informationSurvivorship: Lifestyle Modifications of Diet and Exercise
Survivorship: Lifestyle Modifications of Diet and Exercise Alice S. Ryan, PhD Professor Division of Gerontology and Geriatric Medicine University of Maryland School of Medicine VA Senior Research Career
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationThe National Diabetes Prevention Program in Washington State March 2012
The National Diabetes Prevention Program in Washington State March 2012 Session Objectives 1. Overview of pre-diabetes. 2. Describe the Diabetes Prevention Program (DPP). 3. Eligibility for the DPP. 4.
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationMEDICAL MANAGEMENT 101
MEDICAL MANAGEMENT 101 Christopher Still, DO, FACN, FACP Medical Director, Center for Nutrition & Weight Management Director, Geisinger Obesity Research Institute Geisinger Health Care System Your Weight
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationCorrelations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation
Correlations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation Rachel Ballard-Barbash, MD, MPH Applied Research Program (ARP) Division of Cancer Control and Population
More informationObesity and Cancer Survivorship. Cynthia Thomson, PhD, RD Professor-Mel & Enid Zuckerman College of Public Health University of Arizona
Obesity and Cancer Survivorship Cynthia Thomson, PhD, RD Professor-Mel & Enid Zuckerman College of Public Health University of Arizona Objectives Describe the relationship between obesity, weight gain
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationWhere are We Now? Editor s Note: Who Qualifi es for Obesity Medications?
Obesity Medications Where are We Now? by Christopher D. Still, DO, FACP, FACN, Nadia Boulghassoul-Pietrzykowska, MD, and Jennifer E. Franceschelli, DO Editor s Note: Please note that some of the medications
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationThe B-AHEAD 2 Trial. Randomised controlled trial of intermittent versus continuous energy restriction during adjuvant chemotherapy:
The B-AHEAD 2 Trial Randomised controlled trial of intermittent versus continuous energy restriction during adjuvant chemotherapy: Dr Michelle Harvie Research Dietitian The Nightingale and Prevent Breast
More informationBreast Cancer and the Heart
Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationAnti-Obesity Agents Drug Class Prior Authorization Protocol
Anti-Obesity Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: March 1, 2018 This policy has been developed through review
More informationCardio oncology Double Jeopardy
Cardio oncology Double Jeopardy Edie Pituskin RN MN (NP Adult) PhD NP Forum for Nursing and Allied Health, April 10, 2015 Aims Describe the double jeopardy faced by cancer patients Discuss issues in detection
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationBody Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)
JNCI J Natl Cancer Inst (2015) 107(9): djv179 doi:10.1093/jnci/djv179 First published online June 25, 2015 Article Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741
More informationOncotype DX tools User Guide
Oncotype DX tools User Guide This guide provides an overview of the data and quick access to the Oncotype DX tools Oncotype DX tools offers two quantitative calculator tools that may be used together with
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationExercise Behavior & Major Cardiac Events: CCSS 1 STUDY TITLE
STUDY TITLE Exercise Behavior & Major Cardiac Events: CCSS 1 Association Between Exercise Behavior and Incidence of Major Cardiac Events in Adult Survivors of Childhood Cancer: A Report from the Childhood
More informationImpact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer
Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics
More informationOverview of Management of Obesity
Overview of Management of Obesity Srividya Kidambi, MD, MS Division of Endocrinology, Metabolism, and Clinical Nutrition Medical College of Wisconsin, Milwaukee, WI I have nothing to disclose. Objectives
More informationTreating Type 2 Diabetes by Treating Obesity. Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition
Treating Type 2 Diabetes by Treating Obesity Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition 2 Center Stage Obesity is currently an epidemic in the United States, with
More informationHypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients. Lu Chen
Hypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients Lu Chen A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
More informationObesity and Breast Cancer in a Multiethnic Population. Gertraud Maskarinec, MD, PhD University of Hawaii Cancer Center, Honolulu, HI
Obesity and Breast Cancer in a Multiethnic Population Gertraud Maskarinec, MD, PhD University of Hawaii Cancer Center, Honolulu, HI Background Breast cancer incidence remains lower in many Asian than Western
More informationPhysical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study
DOI 10.1007/s10552-010-9714-3 ORIGINAL PAPER Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study Lisa A. Cadmus Bertram
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationFDA approves Belviq to treat some overweight or obese adults
FDA approves Belviq to treat some overweight or obese adults Silver Spring, MD, USA (June 27, 2012) - The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition
More informationTreating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background
Treating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationWhat is obesity? OBESITY. Obesity is a health issue in which someone has so much extra fat that it negatively impacts their health.
OBESITY What is obesity? Obesity is a health issue in which someone has so much extra fat that it negatively impacts their health. Obesity is most often measured by body mass index (BMI), which looks at
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationMaking Changes: Cognitive Behavior Therapy for Binge Eating Disorder. Michele Laliberte, Ph.D., C.Psych.
Making Changes: Cognitive Behavior Therapy for Binge Eating Disorder Michele Laliberte, Ph.D., C.Psych. Making Changes Week 2 About Weight Outline of Session BED and Obesity Your health and body image
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationConnecting Links for Reducing Risks: Understanding the impact of obesity on cancer development. Kristi Acker, DNP, FNP-BC, AOCNP, ACHPN
Connecting Links for Reducing Risks: Understanding the impact of obesity on cancer development Kristi Acker, DNP, FNP-BC, AOCNP, ACHPN Objectives 1) Identify factors that contribute to the financial burden
More informationFollow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care
Follow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of
More informationWhen Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity
When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity Casey Bonaquist, DO Saturday, April 30 th, 2016 17 th Annual Primary Care & Cardiovascular Symposium Learning Objectives After
More informationRationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York
Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant
More information